GlassScriptPhysician profile
Christine Conner
NPI 1295120533
$2,022.18
in general payments reported to CMS, 2019-2025
19 companies · $860 in 2025
The $860 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $388 · 2023: $404 · 2024: $370 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560 · Education: $74.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.33 |
| Education | $74.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $755.38 | 2022-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $321.71 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.55 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $206.58 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $158.22 | 2023-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $40.91 | 2022-2023 | |
| Grifols USA, LLC | $35.67 | 2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $35.19 | 2025 | Inspire |
| Genentech USA, INC. | $34.69 | 2022-2023 | Xolair |
| Merck Sharp & Dohme LLC | $28.04 | 2025 | Winrevair |
| Insmed, INC. | $26.41 | 2025 | Arikayce |
| Mylan Specialty L.P. | $26.07 | 2022-2023 | Yupelri |
| Philips North America LLC | $25.27 | 2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $22.89 | 2022 | |
| Boston Scientific Corporation | $21.27 | 2024 | Watchman Flx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.32 | 2024 | |
| Idorsia Pharmaceuticals US INC | $19.83 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2022 | |
| Optinose US, INC. | $14.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.